A review published in Frontiers in Psychiatry has identified a significant gap in research on using GLP-1 receptor agonists (GLP-1 RAs) — a class of drugs including semaglutide and liraglutide — to treat weight gain caused by antipsychotic medications in children and adolescents. While the drugs have shown strong results in adults and are approved for adolescent obesity, no studies have yet examined their use specifically for young patients on antipsychotics, according to the review.

Second-generation antipsychotics (SGAs) are widely prescribed to young people for conditions including schizophrenia, bipolar disorder, and irritability associated with autism. Weight gain is a well-documented side effect, and the review notes that children and adolescents may be even more vulnerable to metabolic problems from these drugs than adults. The downstream risks — insulin resistance, type 2 diabetes, and cardiovascular disease — are especially concerning in youth because of the long lifetime of exposure ahead of them.

Current options for managing this weight gain are limited. Lifestyle changes or switching to a different antipsychotic often do not work well, the authors write. For patients on clozapine — a drug used for hard-to-treat psychosis — switching can worsen psychiatric symptoms. Metformin, the most studied pharmacological intervention for antipsychotic-associated weight gain in young people, produces only modest benefits.

GLP-1 RAs work by mimicking a gut hormone that stimulates insulin secretion, slows stomach emptying, and suppresses appetite. In adults taking antipsychotics, multiple randomized controlled trials and meta-analyses have shown that liraglutide and semaglutide significantly reduce body weight and improve blood sugar and cholesterol levels, without worsening psychotic symptoms or affecting drug concentrations. In adolescents with obesity who are not on antipsychotics, the drugs are also effective, with semaglutide producing substantial reductions in body mass index and improvements in several cardiometabolic measures.

Despite this convergence of evidence, the review states that no identified studies have evaluated GLP-1 RAs specifically for antipsychotic-associated weight gain in children or adolescents. The authors, from the NYU Grossman School of Medicine, describe this as a significant evidence gap.

"Any expectation of efficacy in this specific population is not supported by direct pediatric evidence and should be understood throughout this review as an extrapolation from two separate and non-overlapping bodies of literature," the researchers wrote, referring to adult antipsychotic studies and pediatric obesity studies.

The review was a narrative synthesis of clinical trials, meta-analyses, systematic reviews, and regulatory data. The authors searched PubMed/MEDLINE and Google Scholar through June 2026, and also used an AI-based clinical evidence platform and FDA resources.

Gastrointestinal side effects were the most commonly reported adverse events across all studies. The review found no evidence from randomized trials, meta-analyses, or observational studies of an increased risk of adverse psychiatric outcomes linked to GLP-1 RA treatment.

Currently, two GLP-1 RAs are FDA-approved for weight management in adolescents aged 12 and older: liraglutide (Saxenda) and semaglutide (Wegovy). Three others are approved for type 2 diabetes in children aged 10 and older. However, none of these approvals specifically cover weight gain caused by antipsychotic use.

The authors call for prospective, pediatric-specific trials to establish the efficacy, safety, optimal timing, and long-term metabolic and psychiatric outcomes of GLP-1 RA treatment in young people receiving SGAs. Until such studies are conducted, clinicians and families face uncertainty about whether these drugs are a safe and effective option for managing one of the most challenging side effects of essential psychiatric medications in youth.